In 1988, Congress passed the Clinical Laboratory Improvement Amendments (CLIA), the purpose of which was to develop quality standards for laboratories nationwide to ensure that results were reliable, accurate, and reproducible. Subsequent studies regarding CLIA have highlighted improved adherence to quality standards in laboratories nationwide. However, despite the successes of CLIA with regard to laboratory quality standards, some of its provisions have prompted controversy, particularly the more recent use of the tenets to grant analyte status to primary antibodies used in immunohistochemical staining.
The impact of CLIA with regard to primary antibodies is manifested in the College of American Pathology (CAP) implementation of the CAP Survey Checklist ANP 22432, which prohibits the use of primary antibodies beyond the manufacturers' printed expiration dates. Because the Centers for Medicare and Medicaid Services has charged CAP with the role of laboratory accreditation, CLIA and CAP Survey Checklist ANP 22432 have taken a prominent role in immunohistochemistry laboratories nationwide in their efforts to become or remain accredited. Compliance with the CAP Survey Checklist ANP 22432 has challenged large and small laboratories alike because the use of a given antibody varies in frequency, with some antibodies being used rarely. Primary antibodies used infrequently are likely to expire according to the manufacturers' printed expiration dates long before their quantity is consumed, resulting in high overhead cost.
In the current economic environment, in which health care costs are rising at unprecedented rates while institutional and individual budgets are dwindling, the need to use resources wisely has never been greater. Researchers in pathology have long recognized the usefulness of primary antibodies past their printed expiration dates, and use of these reagents has become routine for research purposes. Continually restocking infrequently used antibodies on the basis of their expiration dates in the clinical setting serves to ignore this commonly recognized although unregulated use and contributes to rising health care costs.
Two smaller previous studies in the English literature have examined the use of expiration dates for immunohistochemical studies in the clinical setting, with both demonstrating no significant difference between new and expired reagents. 1, 2 The last of these studies was conducted a decade ago, before the granting of analyte-specific status to primary antibodies, and raises the question of whether the results remain valid today. The current study aimed to investigate the validity of laboratory adherence to the manufacturers' printed expiration dates on primary antibodies with regard to the quality of immunohistochemical results, thereby helping to determine if there is an evidence basis for the CAP Survey Checklist ANP 22432.
Materials and Methods
We used 26 recently acquired antibodies and their expired counterparts (ranging from 6 to 24 months with an average expiration interval of 13 months) to stain consecutive formalin-fixed, paraffin-embedded tissue sections using standard immunohistochemical techniques. Appropriate positive and negative control studies were conducted. First, 4-μm tissue sections were deparaffinized in xylene and dehydrated in graded alcohols. Endogenous peroxidase activity was quenched by immersion in a 3% hydrogen peroxide solution in water for 5 minutes. Epitope retrieval was performed by Proteinase K (DAKO, Carpinteria, CA) digestion, routine microwave treatment in citrate buffer (inhouse preparation), or pressure cooker treatment in citrate buffer (in-house preparation) depending on the antibody to be applied.
Pretreated slides were loaded onto the DAKO Autostainer Plus slide processing instrument. Sections were overlaid with antibody at various dilutions and incubated for 15 to 30 minutes ❚Table 1❚. Sections were developed by using the EnVision+ Systems horseradish-peroxidase 3+  IV  3+  IV  BRST-2  D6  Signet  1:400  2-8  3+  IV  3+  IV  Calretinin  Polyclonal  Zymed  1:200  2-8  3+  IV  2+  IV  Cytokeratin 5/6  IB6  Novocastra  1:200  -80  3+  IV  3+  IV  CD8  C8/144B  DAKO  1:20  2-8  2+  IV  2+  IV  CD21  1F8  DAKO  1:10  2-8  2+  IV  3+  IV  CD43  DF-T1  DAKO  1:200  2-8  3+  IV  3+  IV  CD45RO  UCHL1  DAKO  1:50  2-8  3+  IV  3+  IV  CD68  PG-M1  DAKO  1:200  2-8  3+  IV  3+  IV  CD99  O13  DAKO  1:50  2-8  3+  IV  2+  IV  Collagen IV  23IIC3 polymer technology (DAKO). A chromogenic precipitate was obtained by incubating the slides with Liquid DAB+ (DAKO). A post-DAB enhancer (DAKO) was added. Slides were counterstained with Harris hematoxylin for 3 minutes, rinsed in distilled water, and dipped 5 times in a solution of 0.03% ammonium hydroxide. Slides were coverslipped with a synthetic mounting medium.
Slides were analyzed sequentially by each of us independently, with each slide assessed for staining intensity and the percentage of positive cells. Staining intensity was graded on a 3-point scale (1+-3+), and the percentage of positive cells was graded on a 4-point scale (I, <25% of targeted cells stained; II, 25%-50% of targeted cells stained; III, 50%-75% of targeted cells stained; and IV, ≥75% of targeted cells stained).
Results
Expired reagents performed equal to or better than new primary antibodies in 23 of the 26 antibodies tested (Table 1) .
Staining Intensity
Of the 26 antibodies evaluated, 20 showed no difference between the new and expired reagents ❚Image 1❚, while 3 of the 26 antibodies demonstrated increased staining intensity on slides with the expired reagents ❚Image 2❚. The antibodies with a higher staining intensity seen in the expired reagents included anticalretinin, anti-CD99, and antiprolactin. Of the 26 antibodies examined, 1 demonstrated increased staining intensity on slides with the nonexpired reagents ❚Image 3❚. This antibody was anti-CD21.
Percentage of Cell Positivity
Of the 26 antibodies, 22 showed no difference between the expired and nonexpired reagents, while 1 of the 26 antibodies (antiprolactin) demonstrated an increased percentage of positivity with the expired reagents. The remaining 3 antibodies (anti-HBME, anti-p53, and anti-thyroid-stimulating hormone) demonstrated increased cell positivity on slides with the nonexpired reagents.
Discussion
CLIA and the push for increased quality assurance measures have led to greater intralaboratory reproducibility and reliability and improved patient care. However, they have also raised some issues, one of them being the placement of primary antibodies used in immunohistochemical analysis under the umbrella of analyte-specific reagents and the ensuing restrictions imposed by adherence to the manufacturers' printed expiration dates. Within the clinical and research arenas, pathologists have long acknowledged the usefulness of primary antibodies after their printed expiration dates, and 2 studies published approximately a decade ago, before the analyte-specific reagent status was granted, found no difference between new and expired reagents in the clinical setting. 1,2 To date, no study has fully investigated the issue of post-expiration date primary antibody immunoreactivity in the "analyte-specific-reagent era."
Of the 26 primary antibodies investigated, 23 (88%) of the expired antibody lots performed as well as or better than their new antibody counterparts. Of the 26 primary antibodies, 1 demonstrated increased staining intensity with the new reagents, and 3 of the 26 antibodies showed an increased percentage of positivity when new reagents were used. When differences between staining intensity and the percentage of positivity were recorded, however, none differed by more than 1 increment, making differences clinically negligible. Unlike other clinical laboratory tests in which positive and negative control studies may be performed once for each lot, best practice dictates that antibodies be tested routinely with each use through examination of positive and negative control samples. If positive control samples are deemed unsatisfactory, even if the antibody is within the manufacturer's printed expiration date, evaluation of the clinical specimen is aborted and the test deemed invalid. The quality of the primary antibody is therefore not based on an expiration date, but rather on its performance on a case-by-case basis with appropriate positive and negative control samples. The use and reliance on expiration dates therefore inappropriately groups immunohistochemical studies and primary antibody use with other clinical laboratory tests that rely on automated technology for the generation of results with lot-based controls. This distinctly contrasts with the practice of pathologists using antibody-based testing with case-by-case interpretation and individual case-based positive and negative control samples. These results support the findings published by Balaton et al 1 and Tubbs et al 2 regarding the suitability of expired reagents for clinical use and lend credence to the long-standing use of expired primary antibodies in the research arena. In conjunction with these prior studies, the current study once again challenges the validity and usefulness of the manufacturers' printed expiration dates on antibodies used in immunohistochemical studies. As Balaton et al 1 noted, manufacturer expiration dates indicate the time frame in which a particular reagent has been tested and its quality supported but do not represent the potential life span and quality of the reagent.
Manufacturers have neither the time nor the incentive to adequately evaluate the true life span of primary antibodies used in immunohistochemistry when properly stored. Consequently, reagents are being sold with ever-increasing concentrations and volumes with shrinking expiration time frames, which only serves to fuel rising health care costs. Unfortunately patients, insurance companies, and institutions are left to bear the increased financial burdens. In the current economic environment, in which places to curtail spending are actively being sought, the results of this study support the exemption of primary antibodies from the analyte status imposed by CLIA and encourage revision of the CAP Survey Checklist ANP 22432. This study, along with prior studies, provides evidence for the extension of the shelf life of primary antibodies past the manufacturers' expiration dates, with no detriment to patient care.
